Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
To assess investigator engagement of μCor system data in the context of heart failure management. The μCor system includes a sensor and wearable patch for fluid management.
Subjects meeting the inclusion/exclusion criteria will wear the μCor for up to 90 days.
During the study, face to face follow up will occur every 30 days. For all subjects, each scheduled clinic visit will include assessment of cardiac signs, symptoms, and any relevant clinically actionable events.
The subject will be given a daily diary to track symptoms, hospital visits, medication changes, and all other heart failure related clinical events.
Weekly phone calls to the subject will be given throughout the duration of the study to remind the patient to use the subject diary and to collect and record heart failure related clinical events.
The subject's health care provider team will receive the μCor data through access to a clinical tool interface. The clinical tool will send data updates that are dependent on the μCor data trends. The data updates will allow the health care provider team to take action when the data indicate worsening heart failure, within the context of standard of care medical practice and patient specific parameters. Weekly data reports will be delivered to the investigators.
Subjects will be contacted six months and one year from initial enrollment to assess the vital status of the subject, any heart failure related clinical events since the end of μCor wear, and any health care utilization since the end of μCor wear.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Device Data Engagement Assessment | Experimental | This arm will assess the endpoints of investigator engagement with the device data. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| μCor | Device | μCor consists of the following components: A) Patch B) Sensor C) Charger D) Data transmission device (Gateway) E) Server Once activated, the wearable Sensor automatically acquires ECG, RF readings, heart rate, respiration rate, activity, and posture measurements. |
| Measure | Description | Time Frame |
|---|---|---|
| Number of Data Updates Received by the uCor Subject Management System | Each time a subject's thoracic fluid index (TFI) exceeded a threshold for 3 consecutive days, a data update report was generated by the uCor management system. The site then confirmed its receipt of the data update by completing a case report form. At least 1 of these case report forms was completed for 56 subjects. | 90 days |
| Approximate Time Spent Reviewing Data Reports Assessment Across Sites (PO 2: Part 1/2) | Sites reviewed data reports in each of the following contexts: planned weekly phone call, planned office visit, unplanned phone call, unplanned office visit, and data update. Sites reported whether they spent less than 5, 5 to 10, or greater than 10 minutes reviewing each report. At least 1 of these case report forms was completed for 214 subjects. | 90 days |
| Approximate Time Spent Reviewing Data Reports Assessment Within Sites (PO 2: Part 2/2) | Sites reviewed data reports in each of the following contexts: planned weekly phone call, planned office visit, unplanned phone call, unplanned office visit, and data update. Sites reported whether they spent less than 5, 5 to 10, or greater than 10 minutes reviewing each report. At least 1 of these case report forms was completed for 214 subjects. | 90 days |
| The Number of Medication Changes(MC) and Lifestyle Modifications(LS) Recommended to the Subject Based on Evaluating μCor Data and Symptoms (PO 3: Part 1/3) | Sites reviewed data reports in each of the following contexts: planned weekly phone call, planned office visit, unplanned phone call, unplanned office visit, and data update. In each context, the subject was asked whether their symptoms changed. If yes, the site reported in a case report form whether it took action to treat the subject in the form of a medication change or lifestyle modification. At least one of these case report forms (CRFs) was completed for 214 subjects | 90 days |
| Measure | Description | Time Frame |
|---|---|---|
| Strength of Association Between μCor Measurements and Clinically Related Heart Failure Events. | Definitions: Daytime: 7:00 AM - 12:00 AM Nighttime: 12:00 AM - 7:00 AM For each day on which the subject wore the device, the following values were calculated: Daytime activity: The proportion of minutes while wearing the device that the subject spent active (unitless). Nighttime heart rate: The median heart rate while wearing the device during the night (beats/min) Thoracic fluid index: The median proportion of ratio of radiofrequency-measured lung fluid readings compared to the subject's baseline (unitless). Nighttime posture: The median pitch angle while wearing the device during the night (degrees, where 0 is the horizontal). Nighttime respiration: The median respiration rate while wearing the device during the night (breaths/min) HF event: a hospitalization, emergency room visit, observation unit visit, unplanned clinic visit, or death primarily due to heart failure. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Mike Osz | Zoll Medical Corporation | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| SYED Research Consultants LLC | Sheffield | Alabama | 35660 | United States | ||
| TriWest Research |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | uCor Wearers | Subjects wearing the uCor device |
| Title | Milestones | Reasons Not Completed | |||||
|---|---|---|---|---|---|---|---|
| Overall Study |
|
Not provided
Not provided
| Type | Includes Protocol | Includes SAP | Includes ICF | Document Label | Document Date | Document Uploaded Date | Document File Name |
|---|---|---|---|---|---|---|---|
| Prot_SAP | Yes | Yes | No | Study Protocol and Statistical Analysis Plan | Nov 1, 2019 |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| The Number of Medication Changes(MC) and Lifestyle Modifications(LS) Recommended to the Subject Based on Evaluating μCor Data and Symptoms (PO 3: Part 2/3) | Sites reviewed data reports in each of the following contexts: planned weekly phone call, planned office visit, unplanned phone call, unplanned office visit, and data update. In each context, the subject was asked whether their symptoms changed. If yes, the site reported in a case report form whether it took action to treat the subject in the form of a medication change or lifestyle modification. At least one of these case report forms (CRFs) was completed for 214 subjects. | 90 days |
| The Number of Medication Changes(MC) and Lifestyle Modifications(LS) Recommended to the Subject Based on Evaluating μCor Data and Symptoms (PO 3: Part 3/3) | Sites reviewed data reports in each of the following contexts: planned weekly phone call, planned office visit, unplanned phone call, unplanned office visit, and data update. In each context, the subject was asked whether their symptoms changed. If yes, the site reported in a case report form whether it took action to treat the subject in the form of a medication change or lifestyle modification. At least one of these case report forms (CRFs) was completed for 214 subjects | 90 days |
| The Number of Medication Changes Based on Subject Incidental Findings | During weekly planned phone calls, planned office visits, and unplanned office visits, sites asked subjects whether they underwent any changes to their heart failure and/or cardiac medications since the last phone call and reported the result in a case report form. At least 1 of these case report forms was completed for 241 subjects. | 90 days |
| Number of Times High μCor Measurements Were Reduced Below Threshold Levels After Medication Was Titrated or Lifestyle Modifications Were Recommended | 482 medication changes or lifestyle (MC/LS) modifications occurred within the first 90 days of the study. To include only medication changes preceded and followed by sufficient µCor data to determine a threshold crossing, medication changes within the first 2 weeks of the study or the final 3 weeks of device wear were discarded. This resulted in in 262 analyzable changes. Changes occurring within 1 week of another change were grouped together. This resulted in 192 change events. Time windows were defined as 0-13 days before the first change in a change event vs. 8-21 days after the last change in a change event. A high μCor measurement was defined as the receipt of a data update by the site. A low μCor measurement was defined as the absence of a data update received by the site. | 90 days |
| 90 days |
| Strength of Association Between μCor Measurements and Subject Reported Symptoms | During office visits at months 1, 2, and 3, subjects reported their degrees of dyspnea, orthopnea, and fatigue on the following scale: [none, seldom, frequent, continuous]. Each day that the subject wore the device, a daily median was calculated for the following measures: [thoracic fluid index, nighttime heart rate, nighttime respiration rate]. Nighttime was defined as 12:00 AM - 7:00 AM. | 90 days |
| Correlations Between uCor Measurements and Patient Reported Symptoms: Mild/Severe Symptoms | During office visits at months 1, 2, and 3, subjects reported their degrees of dyspnea, orthopnea, and fatigue on the following scale: [none, seldom, frequent, continuous]. | 90 days |
| Hospital Readmission Rate, Physician Visit Rate, and Outpatient Clinic Visit Rate During the Study Period | For each weekly phone call and monthly office visit, each subject reported whether they experienced a hospitalization or emergency room visit since their last call/visit. An adjudication committee of physicians determined whether each event was due to HF or not. | 90 days |
| Mortality Rate, Heart Failure Related Events, Quality of Life (QoL) and Healthcare Utilization Data at 6 Months and One Year Post Enrollment: Mortality Data | On each subject's final date of study participation, their survival status was recorded. | 6 months and 1 year |
| Mortality Rate, Cause of Death, Quality of Life (QoL) and Healthcare Utilization Data at 6 Months and One Year Post Enrollment: Cause of Death | On each subject's final date of study participation, in the case of death, the cause of death was recorded. | 6 months and 1 year |
| Mortality Rate, Heart Failure Related Events, Quality of Life (QoL) and Healthcare Utilization Data at 6 Months and One Year Post Enrollment: Quality of Life Data | At 0 months, 6 months, and 1 year after enrollment, subjects completed a Kansas City Cardiomyopathy Questionnaire (KCCQ-12). Quality of life is calculated as: KCCQ12-QL = 100*[(average of Questions 6 and 7) - 1]/4 Score is scaled 0-100, where 0 denotes the lowest reportable health status and 100 the highest. | 6 months and 1 year |
| Mortality Rate, Heart Failure Related Events, Quality of Life (QoL) and Healthcare Utilization Data at 6 Months and One Year Post Enrollment: Healthcare Utilization Data | For each weekly phone call, monthly office visit, 6-month phone call, and 1-year phone call, each subject reported whether they experienced a hospitalization, emergency room visit, or unplanned doctor's office visit since their last call/visit. | 6 months and 1 year |
| El Cajon |
| California |
| 92020 |
| United States |
| Zillan Clinical Research | Inglewood | California | 90301 | United States |
| Axis Clinical Trials | Los Angeles | California | 90036 | United States |
| InvivoCure LLC | Mission Hills | California | 91345 | United States |
| ACRC Studies | San Diego | California | 92119 | United States |
| Aventura Clinical Research LLC | Aventura | Florida | 33180 | United States |
| Accel Research Sites - Guardian | Davenport | Florida | 33837 | United States |
| Accel Research Sites- Daytona Heart Group | DeLand | Florida | 32720 | United States |
| Accel Research Sites - Guardian Winter Park | Deltona | Florida | 32725 | United States |
| Holy Cross Hospital, Medical Group, Cardiology Associates | Fort Lauderdale | Florida | 33308 | United States |
| Elite Cardiac Research Center | Hialeah | Florida | 33013 | United States |
| Inpatient Research Clinic | Hialeah | Florida | 33013 | United States |
| Homestead Associates in Research | Miami | Florida | 32032 | United States |
| Westchester Research Center at Westchester General Hospital | Miami | Florida | 33155 | United States |
| Miramax Clinical Research Inc | North Miami | Florida | 33169 | United States |
| Ocala Cardiovascular Research | Ocala | Florida | 34471 | United States |
| Accel Research Sites | Orlando | Florida | 32837 | United States |
| DBC Research | Tamarac | Florida | 33321 | United States |
| Winter Haven Hospital - BayCare Health System | Winter Haven | Florida | 33880 | United States |
| Accel Research Sites - Guardian Winter Park | Winter Park | Florida | 32792 | United States |
| Emory University School of Medicine | Atlanta | Georgia | 30303 | United States |
| Columbus Cardiology Associates | Columbus | Georgia | 31904 | United States |
| Accel Research Sites - Lake County Medical Group | Eatonton | Georgia | 31024 | United States |
| Quincy Medical Group | Quincy | Illinois | 62301 | United States |
| Cardiovascular Research of Northwest Indiana, LLC | Munster | Indiana | 46321 | United States |
| Reid Physician Associates | Richmond | Indiana | 47374 | United States |
| Beacon Medical Group | South Bend | Indiana | 46601 | United States |
| Norton Heart Specialists | Louisville | Kentucky | 40205 | United States |
| Research Integrity, LLC | Owensboro | Kentucky | 42303 | United States |
| Heart Clinic of Hammond | Hammond | Louisiana | 70403 | United States |
| Sinai Center for Thrombosis Reserach and Drug Development | Baltimore | Maryland | 21784 | United States |
| Intervent Clinical Research Center | Pembroke Hills | Maryland | 33024 | United States |
| Peninsula Regional Medical Center | Salisbury | Maryland | 21804 | United States |
| Ascension Providence Rochester Hospital | Rochester | Michigan | 48307 | United States |
| Ascension St. Mary's Research Institute | Saginaw | Michigan | 48601 | United States |
| Jackson Heart Clinic | Jackson | Mississippi | 48601 | United States |
| Kansas City Cardiology | Lee's Summit | Missouri | 64064 | United States |
| Gateway Cardiovascular Research Center, Inc | St Louis | Missouri | 63128 | United States |
| St. Louis Heart and Vascular | St Louis | Missouri | 63136 | United States |
| Bryan Heart | Lincoln | Nebraska | 68506 | United States |
| Methodist Physicians Clinical Heart Consultants | Omaha | Nebraska | 68114 | United States |
| Virtua Health | Cherry Hill | New Jersey | 08034 | United States |
| Hackensack University Medical Center | Hackensack | New Jersey | 07601 | United States |
| Jersey Shore University Medical Center | Neptune City | New Jersey | 07753 | United States |
| Bassett Medical Center | Cooperstown | New York | 13326 | United States |
| Laurelton Heart Specialist | Rosedale | New York | 11422 | United States |
| BronxCare Health System at BronxCare Hospital Center | The Bronx | New York | 10457 | United States |
| Macklenberg Heart Specialists / Focus Clinical Research Solutions | Charlotte | North Carolina | 28207 | United States |
| Heart House Research Foundation | Springfield | Ohio | 45504 | United States |
| Mercy Health St. Vincent Medical Center | Toledo | Ohio | 43608 | United States |
| INTEGRIS Baptist Medical Center | Oklahoma City | Oklahoma | 73112 | United States |
| Penn State Health Milton S. Hershey Medical Center | Hershey | Pennsylvania | 17033 | United States |
| Mercer Bucks Cardiology at Jefferson Health | Newtown | Pennsylvania | 18940 | United States |
| Cardiovascular Institute | Pittsburgh | Pennsylvania | 15212 | United States |
| Frontier Clinical Research, LLC | Smithfield | Pennsylvania | 15478 | United States |
| Carolina Heart Specialists | Lancaster | South Carolina | 77598 | United States |
| Knoxville HMA Cardiology, PPM, LLC | Knoxville | Tennessee | 37934 | United States |
| North Texas Research Associates | Allen | Texas | 75013 | United States |
| North Houston Cardiology Center | Cypress | Texas | 77429 | United States |
| JPS Health Network | Fort Worth | Texas | 76104 | United States |
| North Texas Research Associates | McKinney | Texas | 75071 | United States |
| Texas Institute of Cardiology | McKinney | Texas | 75071 | United States |
| Mission Research Institue | New Braunfels | Texas | 78130 | United States |
| Bay Area Heart | Webster | Texas | 77598 | United States |
| Stroobants Cardiovascular Center | Lynchburg | Virginia | 24501 | United States |
| Pulse Heart Institute | Puyallup | Washington | 98372 | United States |
| Klinikum Klagenfurt am Wörthersee | Klagenfurt | 9020 | Austria |
| Klinik Favoriten | Vienna | 1100 | Austria |
| Centre Hospitalier Régional Universitaire de Lille - Hôpital Cardiologique | Lille | 59037 | France |
| CHU Montpellier - Hopital Arnaud de Villeneuve | Montpellier | 34295 | France |
| Chu Montpellier - Hopital Arnaud de Villeneuve | Montpellier | France |
| Hôpital Européen Georges Pompidou - Centre d'Investigations Cliniques - Pôle D - étage 5 | Paris | 75015 | France |
| Hôpital Européen Georges Pompidou - Centre d'Investigations Cliniques - Pôle D - étage 5 | Paris | France |
| Albertinen Krankenhaus HH | Hamburg | GG | 22457 | Germany |
| Kerckhoff-Klinik GmbH | Bad Nauheim | 06032 | Germany |
| Kerckhoff-Klinik GmbH | Bad Nauheim | Germany |
| Universitätsklinikum Frankfurt | Frankfurt am Main | 60590 | Germany |
| Universitätsklinikum Gießen und Marburg GmbH | Giessen | 35392 | Germany |
| Albertinen Krankenhaus Hamburg | Hamburg | Germany |
| Medizinische Hochschule Hannover | Hanover | 30625 | Germany |
| Medizinische Hochschule Hannover | Hanover | Germany |
| Herzzentrum Leipzig, Universitätsklinik für Kardiologie Abteilung Rhythmologie | Leipzig | 4289 | Germany |
| COMPLETED |
|
| NOT COMPLETED |
|
|
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | uCor Wearers | Subjects wearing the uCor device |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | Mean | Standard Deviation | years |
| ||||||||||||||||||||||
| Sex: Female, Male | Count of Participants | Participants |
| |||||||||||||||||||||||
| Race/Ethnicity, Customized | Participant could identify as more than one ethnicity and may be counted in more than one ethnic category. | Number | participants |
| ||||||||||||||||||||||
| Weight | Mean | Standard Deviation | pounds |
| ||||||||||||||||||||||
| Height | Mean | Standard Deviation | inches |
| ||||||||||||||||||||||
| Blood Pressure (Systolic) | Mean | Standard Deviation | mmHg |
| ||||||||||||||||||||||
| Blood Pressure (Diastolic) | Mean | Standard Deviation | mmHg |
| ||||||||||||||||||||||
| Heart Rate (per min) | Mean | Standard Deviation | beats per minute |
| ||||||||||||||||||||||
| Respiratory Rate (per min) | Mean | Standard Deviation | breaths per minute |
| ||||||||||||||||||||||
| Time Since Heart Failure Diagnosis | Mean | Standard Deviation | years |
| ||||||||||||||||||||||
| Ejection Fraction (Min) | Mean | Standard Deviation | percent of ejection fraction |
| ||||||||||||||||||||||
| Ejection Fraction (Max) | Mean | Standard Deviation | percent of ejection fraction |
| ||||||||||||||||||||||
| New York Heart Association(NYHA) Class | The New York Heart Association (NYHA) Functional Classification places patients in 1 of 4 categories based on limitations of physical activity. The healthcare practitioner assigns the patient. I= No limitation of physical activity. II= Slight limitation of physical activity. III= Marked limitation of physical activity. IV= Symptoms of heart failure at rest- Any physical activity causes further discomfort. | Count of Participants | Participants |
| ||||||||||||||||||||||
| Heart Failure Etiology | Count of Participants | Participants |
| |||||||||||||||||||||||
| Educational Level | Count of Participants | Participants |
| |||||||||||||||||||||||
| Employment Status | Count of Participants | Participants |
| |||||||||||||||||||||||
| Cardiac Device History | Count of Participants | Participants |
| |||||||||||||||||||||||
| History of Remote Heart Failure(HF) Monitor | Number | participants |
| |||||||||||||||||||||||
| History of Hypertension | Count of Participants | Participants |
| |||||||||||||||||||||||
| History of Diabetes | Count of Participants | Participants |
| |||||||||||||||||||||||
| History of Chronic Obstructive Pulmonary Disease (COPD) | Count of Participants | Participants |
| |||||||||||||||||||||||
| History of Transient Ischemic Attack (TIA) | Count of Participants | Participants |
| |||||||||||||||||||||||
| History of Chronic Kidney Disease (CKD) | Count of Participants | Participants |
| |||||||||||||||||||||||
| History of Angina | Count of Participants | Participants |
| |||||||||||||||||||||||
| History of Syncope | Count of Participants | Participants |
| |||||||||||||||||||||||
| History of Sudden Cardiac Arrest (SCA) | Count of Participants | Participants |
| |||||||||||||||||||||||
| History of Arrhythmia | Count of Participants | Participants |
| |||||||||||||||||||||||
| History of Myocardial Infarction (MI) | Count of Participants | Participants |
| |||||||||||||||||||||||
| History of Coronary Artery Bypass Graft (CABG) | Count of Participants | Participants |
| |||||||||||||||||||||||
| History of Percutaneous Coronary Intervention (PCI) | Count of Participants | Participants |
|
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | ||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Number of Data Updates Received by the uCor Subject Management System | Each time a subject's thoracic fluid index (TFI) exceeded a threshold for 3 consecutive days, a data update report was generated by the uCor management system. The site then confirmed its receipt of the data update by completing a case report form. At least 1 of these case report forms was completed for 56 subjects. | data updates per subject | Posted | Median | Inter-Quartile Range | data updates per subject | 90 days | data updates | data updates |
|
|
| |||||||||||||||||||||||||
| Primary | Approximate Time Spent Reviewing Data Reports Assessment Across Sites (PO 2: Part 1/2) | Sites reviewed data reports in each of the following contexts: planned weekly phone call, planned office visit, unplanned phone call, unplanned office visit, and data update. Sites reported whether they spent less than 5, 5 to 10, or greater than 10 minutes reviewing each report. At least 1 of these case report forms was completed for 214 subjects. | Posted | Count of Units | Number of data reports | 90 days | Number of data reports | Number of data reports |
|
| ||||||||||||||||||||||||||||
| Primary | Approximate Time Spent Reviewing Data Reports Assessment Within Sites (PO 2: Part 2/2) | Sites reviewed data reports in each of the following contexts: planned weekly phone call, planned office visit, unplanned phone call, unplanned office visit, and data update. Sites reported whether they spent less than 5, 5 to 10, or greater than 10 minutes reviewing each report. At least 1 of these case report forms was completed for 214 subjects. | Most common amount of time spent reviewing by each site | Posted | Number | number of sites | 90 days | number of sites | number of sites |
|
| |||||||||||||||||||||||||||
| Primary | The Number of Medication Changes(MC) and Lifestyle Modifications(LS) Recommended to the Subject Based on Evaluating μCor Data and Symptoms (PO 3: Part 1/3) | Sites reviewed data reports in each of the following contexts: planned weekly phone call, planned office visit, unplanned phone call, unplanned office visit, and data update. In each context, the subject was asked whether their symptoms changed. If yes, the site reported in a case report form whether it took action to treat the subject in the form of a medication change or lifestyle modification. At least one of these case report forms (CRFs) was completed for 214 subjects | Number of medication changes or lifestyle modifications per subject based on μCor data and symptoms | Posted | Count of Units | number of MC/LS changes | 90 days | number of MC/LS changes | number of MC/LS changes |
|
| |||||||||||||||||||||||||||
| Primary | The Number of Medication Changes(MC) and Lifestyle Modifications(LS) Recommended to the Subject Based on Evaluating μCor Data and Symptoms (PO 3: Part 2/3) | Sites reviewed data reports in each of the following contexts: planned weekly phone call, planned office visit, unplanned phone call, unplanned office visit, and data update. In each context, the subject was asked whether their symptoms changed. If yes, the site reported in a case report form whether it took action to treat the subject in the form of a medication change or lifestyle modification. At least one of these case report forms (CRFs) was completed for 214 subjects. | Number of subjects with medication changes based on μCor data and symptoms | Posted | Count of Participants | Participants | 90 days |
|
| |||||||||||||||||||||||||||||
| Primary | The Number of Medication Changes(MC) and Lifestyle Modifications(LS) Recommended to the Subject Based on Evaluating μCor Data and Symptoms (PO 3: Part 3/3) | Sites reviewed data reports in each of the following contexts: planned weekly phone call, planned office visit, unplanned phone call, unplanned office visit, and data update. In each context, the subject was asked whether their symptoms changed. If yes, the site reported in a case report form whether it took action to treat the subject in the form of a medication change or lifestyle modification. At least one of these case report forms (CRFs) was completed for 214 subjects | Number of subjects with lifestyle modifications based on μCor data and symptoms | Posted | Count of Participants | Participants | 90 days |
|
| |||||||||||||||||||||||||||||
| Primary | The Number of Medication Changes Based on Subject Incidental Findings | During weekly planned phone calls, planned office visits, and unplanned office visits, sites asked subjects whether they underwent any changes to their heart failure and/or cardiac medications since the last phone call and reported the result in a case report form. At least 1 of these case report forms was completed for 241 subjects. | Subjects with Medication Changes (MC) based on incidental findings | Posted | Count of Participants | Participants | 90 days |
|
| |||||||||||||||||||||||||||||
| Primary | Number of Times High μCor Measurements Were Reduced Below Threshold Levels After Medication Was Titrated or Lifestyle Modifications Were Recommended | 482 medication changes or lifestyle (MC/LS) modifications occurred within the first 90 days of the study. To include only medication changes preceded and followed by sufficient µCor data to determine a threshold crossing, medication changes within the first 2 weeks of the study or the final 3 weeks of device wear were discarded. This resulted in in 262 analyzable changes. Changes occurring within 1 week of another change were grouped together. This resulted in 192 change events. Time windows were defined as 0-13 days before the first change in a change event vs. 8-21 days after the last change in a change event. A high μCor measurement was defined as the receipt of a data update by the site. A low μCor measurement was defined as the absence of a data update received by the site. | MC/LS events preceded by a high uCor measurement within -13 to 0 days | Posted | Count of Units | MC/LS change events | 90 days | MC/LS change events | MC/LS change events |
|
| |||||||||||||||||||||||||||
| Secondary | Strength of Association Between μCor Measurements and Clinically Related Heart Failure Events. | Definitions: Daytime: 7:00 AM - 12:00 AM Nighttime: 12:00 AM - 7:00 AM For each day on which the subject wore the device, the following values were calculated: Daytime activity: The proportion of minutes while wearing the device that the subject spent active (unitless). Nighttime heart rate: The median heart rate while wearing the device during the night (beats/min) Thoracic fluid index: The median proportion of ratio of radiofrequency-measured lung fluid readings compared to the subject's baseline (unitless). Nighttime posture: The median pitch angle while wearing the device during the night (degrees, where 0 is the horizontal). Nighttime respiration: The median respiration rate while wearing the device during the night (breaths/min) HF event: a hospitalization, emergency room visit, observation unit visit, unplanned clinic visit, or death primarily due to heart failure. | The median was calculated for the 7 days prior to the 1st heart failure (HF) event; the median was calculated for the final 7 days of device wear. ROC analysis was performed. Data are presented assuming that the device reading in subjects without events is less than that of subjects with events. Unit of measure: probability that a randomly chosen subject with severe symptoms has a greater device value than a randomly chosen subject with mild symptoms. | Posted | Number | 95% Confidence Interval | probability | 90 days |
| |||||||||||||||||||||||||||||
| Secondary | Strength of Association Between μCor Measurements and Subject Reported Symptoms | During office visits at months 1, 2, and 3, subjects reported their degrees of dyspnea, orthopnea, and fatigue on the following scale: [none, seldom, frequent, continuous]. Each day that the subject wore the device, a daily median was calculated for the following measures: [thoracic fluid index, nighttime heart rate, nighttime respiration rate]. Nighttime was defined as 12:00 AM - 7:00 AM. | The median of the daily medians for each device measure was calculated for the 7 days preceding each office visit. To assess whether reports of severe [frequent or continuous] symptoms were associated with greater device measures than reports of mild symptoms [none or seldom], ROC analysis was performed. Unit of measure: probability that a randomly chosen subject with severe symptoms has a greater device value than a randomly chosen subject with mild symptoms. | Posted | Number | 95% Confidence Interval | probability | 90 days |
|
| ||||||||||||||||||||||||||||
| Secondary | Correlations Between uCor Measurements and Patient Reported Symptoms: Mild/Severe Symptoms | During office visits at months 1, 2, and 3, subjects reported their degrees of dyspnea, orthopnea, and fatigue on the following scale: [none, seldom, frequent, continuous]. | Each of the 249 participants in the study could contribute data to either Arm/Group depending on the severity of their symptoms across the 3-month study duration. | Posted | Number | Symptom reports | 90 days |
|
| |||||||||||||||||||||||||||||
| Secondary | Hospital Readmission Rate, Physician Visit Rate, and Outpatient Clinic Visit Rate During the Study Period | For each weekly phone call and monthly office visit, each subject reported whether they experienced a hospitalization or emergency room visit since their last call/visit. An adjudication committee of physicians determined whether each event was due to HF or not. | Subjects who had hospital readmission, physician visit, and/or outpatient clinic visit during the study period | Posted | Count of Participants | Participants | 90 days |
|
| |||||||||||||||||||||||||||||
| Secondary | Mortality Rate, Heart Failure Related Events, Quality of Life (QoL) and Healthcare Utilization Data at 6 Months and One Year Post Enrollment: Mortality Data | On each subject's final date of study participation, their survival status was recorded. | Descriptive statistics around mortality rate, cause of death, quality of life (QoL), and health care utilization among patients six months and one year after enrollment into the study. | Posted | Count of Participants | Participants | 6 months and 1 year |
|
| |||||||||||||||||||||||||||||
| Secondary | Mortality Rate, Cause of Death, Quality of Life (QoL) and Healthcare Utilization Data at 6 Months and One Year Post Enrollment: Cause of Death | On each subject's final date of study participation, in the case of death, the cause of death was recorded. | Descriptive statistics around mortality rate, cause of death, quality of life (QoL), and health care utilization among patients six months and one year after enrollment into the study. | Posted | Number | Deaths | 6 months and 1 year | Deaths | Deaths |
|
| |||||||||||||||||||||||||||
| Secondary | Mortality Rate, Heart Failure Related Events, Quality of Life (QoL) and Healthcare Utilization Data at 6 Months and One Year Post Enrollment: Quality of Life Data | At 0 months, 6 months, and 1 year after enrollment, subjects completed a Kansas City Cardiomyopathy Questionnaire (KCCQ-12). Quality of life is calculated as: KCCQ12-QL = 100*[(average of Questions 6 and 7) - 1]/4 Score is scaled 0-100, where 0 denotes the lowest reportable health status and 100 the highest. | Descriptive statistics around mortality rate, cause of death, quality of life (QoL), and health care utilization among patients six months and one year after enrollment into the study. | Posted | Mean | Standard Deviation | score on a scale | 6 months and 1 year |
| |||||||||||||||||||||||||||||
| Secondary | Mortality Rate, Heart Failure Related Events, Quality of Life (QoL) and Healthcare Utilization Data at 6 Months and One Year Post Enrollment: Healthcare Utilization Data | For each weekly phone call, monthly office visit, 6-month phone call, and 1-year phone call, each subject reported whether they experienced a hospitalization, emergency room visit, or unplanned doctor's office visit since their last call/visit. | All subjects in the study from the timepoint of enrollment until end of study participation. | Posted | Number | participants | 6 months and 1 year |
|
|
1 year + 30 days, per subject
All device related adverse effects will be recorded during the study. All adverse device effects (ADEs) will be classified by the investigator as anticipated or unanticipated. Adverse events will also include any adverse events related to medication changes and medical procedures initiated by μCor data.
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Single-Arm, Eligible Subjects | Subjects hospitalized for acute decompensated heart failure and enrolled in the study within 10 days post-hospital discharge. All subjects require an additional heart failure event within the previous 180 days. | 37 | 265 | 0 | 265 | 106 | 265 |
Not provided
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Skin Irritation | Skin and subcutaneous tissue disorders | Systematic Assessment |
|
This study was conducted from 11/1/2019 to 6/30/2023 and partially overlapped with the COVID-19 Pandemic.
Not provided
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Director of Scientific Affairs | ZOLL Medical | 4129683333 | 14410 | nbianco@zoll.com |
| Jun 28, 2024 |
| Prot_SAP_000.pdf |
Not provided
| ID | Term |
|---|---|
| D006333 | Heart Failure |
| ID | Term |
|---|---|
| D006331 | Heart Diseases |
| D002318 | Cardiovascular Diseases |
Not provided
Not provided
| Caucasian |
|
| Black or African American |
|
| Other |
|
| Don't Know/ No Response |
|
| Hispanic/ Latino |
|
| Class III |
|
| Class IV |
|
| Not Documented |
|
| Mixed |
|
| N/A or Unknown |
|
| Bachelors or Associates |
|
| Graduate or Professional |
|
| N/A or Unknown |
|
| Homemaker |
|
| Unemployed |
|
| Retired |
|
| N/A or Unknown |
|
| ICD Active at Enrollment |
|
| History of Pacemaker |
|
| Pacemaker Active at Enrollment |
|
| Uknown |
|
| Unknown |
|
| Unknown |
|
| Unknown |
|
| Unknown |
|
| Unknown |
|
| Unknown |
|
| Unknown |
|
| Unknown |
|
| Unknown |
|
| Unknown |
|
| Unknown |
|
| Number of data reports |
|
|
| number of sites |
|
|
| number of MC/LS changes |
|
|
|
|
|
| MC/LS change events |
|
|
| Units | Counts |
|---|---|
| Participants |
|
|
|
|
|
|
| Deaths |
|
|
| Units | Counts |
|---|---|
| Participants |
|
|
|